Adjuvant Effect of Orally Applied Preparations Containing Non-Digestible Polysaccharides on Influenza Vaccination in Healthy Seniors: A Double-Blind, Randomised, Controlled Pilot Trial
2021
Laue, Christiane | Stevens, Yala | van Erp, Monique | Papazova, Ekaterina | Soeth, Edlyn | Pannenbeckers, Angelika | Stolte, Ellen | Böhm, Ruwen | Le Gall, Sophie | Falourd, Xavier | Ballance, Simon | Knutsen, Svein | Pinheiro, Iris | Possemiers, Sam | Ryan, Paul | Ross, R. Paul | Stanton, Catherine | Wells, Jerry | Werf, Sylvie van Der | Mes, Jurriaan | Schrezenmeir, Juergen | Clinical Research Center Kiel [Rheinland-Pfalz, Germany] ; Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU) | BioActor [Maastricht] | Wageningen University and Research [Wageningen] (WUR) | Unité de recherche sur les Biopolymères, Interactions Assemblages (BIA) ; Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE) | Norwegian Institute of Food,Fisheries and Aquaculture Research (NOFIMA) | ProDigest [Ghent, Belgium] | Teagasc Food Research Centre [Fermoy, Ireland] | University College Cork (UCC) | Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)) ; Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité) | Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur) ; Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité) | This research was funded by the European Community’s Seventh Framework Programme [FP7/2007-2013] ‘EU FibeBiotics’ under Grant Agreement number 289517 | European Project: 289517,EC:FP7:KBBE,FP7-KBBE-2011-5,FIBEBIOTICS(2012)
International audience
Mostrar más [+] Menos [-]Inglés. Senior individuals can suffer from immunosenescence and novel strategies to bolster the immune response could contribute to healthy ageing. In this double-blind, randomised, controlled pilot trial, we investigated the ability of non-digestible polysaccharide (NPS) preparations to enhance the immune response in a human vaccination model. In total, 239 subjects (aged 50–79 years) were randomised to consume one of five different NPS (yeast β-glucan (YBG), shiitake β-glucan (SBG), oat β-glucan (OBG), arabinoxylan (AX), bacterial exopolysaccharide (EPS)) or control (CTRL) product daily for five weeks. After two weeks of intervention, subjects were vaccinated with seasonal influenza vaccine. The post-vaccination increases in haemagglutination inhibition antibody titres and seroprotection rate against the influenza strains were non-significantly enhanced in the NPS intervention groups compared to CTRL. Specifically, a trend towards a higher mean log2 fold increase was observed in the AX group (uncorrected p = 0.074) combined with a trend for an increased seroprotection rate, AX group (48.7%) compared to CTRL (25.6%) (uncorrected p = 0.057), for the influenza A H1N1 strain. Subjects consuming AX also had a reduced incidence of common colds compared to CTRL (1 vs. 8; p = 0.029 in Fisher exact test). No adverse effects of NPS consumption were reported. The findings of this pilot study warrant further research to study AX as an oral adjuvant to support vaccine efficacy.
Mostrar más [+] Menos [-]Palabras clave de AGROVOC
Información bibliográfica
Este registro bibliográfico ha sido proporcionado por Institut national de la recherche agronomique